⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879271 | 0.75 | — | — | |
| SCHEMBL29230012 | 0.73 | — | — | |
| SCHEMBL29011128 | 0.70 | — | — | |
| SCHEMBL709441 | 0.67 | — | — | |
| SCHEMBL12386530 | 0.67 | — | — | |
| SCHEMBL514012 | 0.67 | — | — | |
| SCHEMBL14080933 | 0.67 | — | — | |
| SCHEMBL516766 | 0.67 | — | — | |
| SCHEMBL4427937 | 0.67 | — | — | |
| SCHEMBL195849 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4514803-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| CN-118834213-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-117157299-B | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| CN-117157299-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023208092-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-11-02 | — | — | WO | disclosed |
| CN-113272309-A | Tricyclic inhibitors of hepatitis B virus | 圣拉斐尔医院有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9175260-B2 | Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (MMC) | TheUniversity of Georgia Research Foundation, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-1979314-B1 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7932284-B2 | Indole sulfonamide modulators of progesterone receptors | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
| WO-2008109007-A1 | BRIDGED PHENANTHRIDINES | CARA THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007087488-A9 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2008-08-28 | — | — | WO | disclosed |
| US-4584371-A | Catalytic process for preparing 3-ester-methyl cephalosporins from desacetyl-7-aminocephalosporanic acid | THE UPJOHN COMPANY (US) | 1986-04-22 | — | — | US | disclosed |
| EP-0153874-A2 | Cephalosporin intermediates and their preparation | THE UPJOHN COMPANY (US) | 1985-09-04 | — | — | EP | disclosed |